Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45267, United States; Division of Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, United States. Electronic address: [Email]
Intravenous bisphosphonates (IV BP) have been used to treat children with osteoporosis for many years. Favorable side effect profile and improvements in bone mineral density (BMD) have been demonstrated in patients with osteogenesis imperfecta (OI), a primary form of osteoporosis in pediatrics. Less is known about the safety of IV BP in children with secondary osteoporosis or glucocorticoid-induced osteoporosis (GIO). We aimed to determine the prevalence of both acute and long-term side effects and assess the efficacy of IV BP treatment to increase bone mineral density in pediatric patients with varying presentations of compromised bone health.